Cisapride-induced torsades de pointes

Journal of Cardiovascular Electrophysiology

Volumn 9, Issue 10, 1998, Pages 1109-1113

  Vitola, João ^a   Vukanovic, Jasminka ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisapride; Potassium channels; Torsades de pointes

Indexed keywords

CISAPRIDE; PROPAFENONE; TIMOLOL;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG TRANSFORMATION; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; SYNCOPE; TORSADE DES POINTES;

EID: 0031756069     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1998.tb00888.x     Document Type: Article

References (39)

1. Tan HL, Hou CJ, Lauer MR, et al: Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995;122: 701-714.
2. Roden DM: Current status of class III antiarrhythmic therapy. Am J Cardiol 1993;72:44B-49B.
3. Annese V, Lombardi G, Frusciante V, et al: Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997;11:599-603.
4. Sjogren RW: Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8:569-575.
5. Minami T, Nishibayashi H, Shinomura Y, et al: Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996;31:855-859.
6. Camilleri M: Gastrointestinal problems in diabetes. Endocrinol Metab Clin North Am 1996;25:361-378.
7. Mearin F, Malagelada JR: Gastroparesis and dyspepsia in patients with diabetes mellitus. (Review) Eur J Gastroenterol Hepatol 1995;7:717-723.
8. Olsson S, Edwards IR: Tachycardia during cisapride treatment. Br Med J 1992;305:748-749.
9. Bran S, Murray WA, Hirsch IB, et al: Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-768.
10. Lewin MB, Bryant RM, Fenrich AL, et al: Cisapride-induced long QT interval. J Pediatr 1996;128:279-281.
11. Klausner MA, and Janssen Pharmaceutical Research Foundation. Dear Doctor Letter.
12. Wysowski DK, Bacsanyi J: Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-291.
13. Bedford TA, Rowbotham DJ: Cisapride - Drug interactions of clinical significance. Drug Saf 1996;15: 167-175.
14. Woosley RL, Chen Y, Freiman JP, et al: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269:1532-1536.
15. Crumb WJ Jr, Wible B, Arnold DJ, et al: Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 1995; 47:181-190.
16. + channel cloned from human heart. Mol Pharmacol 1993;44:1240-1245.
17. Yang T, Prakash C, Roden DM, et al: Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995;115:267-274.
18. Roy ML, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94:817-823.
19. Honig PK, Woosley RL, Zamani K, et al: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-238.
20. Honig PK, Wortham DC, Zamani K, et al: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269: 1513-1518.
21. Zimmermann M, Duruz H, Guinand O, et al: Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002-1003.
22. Monahan BP, Ferguson CL, Killeavy ES, et al: Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-2790.
23. Honig PK, Wortham DC, Hull R, et al: Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-1206.
24. Benton RE, Honig PK, Zamani K, et al: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-388.
25. Corinaldesi R, Stanghellini V, Tosetti C, et al: The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993;44:429-432.
26. Carlsson L, Amos GJ, Andersson B, et al: Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro - Implications for proarrhythmic potential. J Pharmacol Exp Ther 1997;282:220-227.
27. Puisieux FL, Adamantidis MM, Dumotier BM, et al: Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996;117:1377-1379.
28. Lopez JA, Harold JG, Rosenthal MG, et al: QT prolongation and Torsades de Pointes after administration of trimethoprim-sulfametroxazole. Am J Cardiol 1987; 59:376-377.
29. Roden DM, Lazzara R, Rosen MR, et al, and the SADS Foundation Task Force on LQTS: Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996;94:1996-2012.
30. Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
31. Nattel S, Ranger S, Talajic M, et al: Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235-238.
32. Rubart M, Pressler ML, Pride HP, et al: Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-1844.
33. McComb JM, Campbell NPS, Cleland J: Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984;54:922-923.
34. Kr potassium channel. Cell 1995;81:299-307.
35. Napolitano C, Priori SG, Schwartz PJ, et al: Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes. (Abstract) Circulation 1997;96:I-211.
36. Schultz-Bahr E, Haverkamp W, Hordt M, et al: Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? (Abstract) Circulation 1997;96:I-211.
37. Eichelbaum M, Gross AS: The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects. Pharmacol Ther 1990;46:377-394.
38. Mörike KE, Roden DM: Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther 1994;55:28-34.
39. Edeki TI, He H, Wood AJ: Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611-1613.